Company news

Axogen, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Axogen Inc. Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration (FDA) for Avance Nerve Graft®

May 15, 2024

Axogen, Inc to Participate at Leerink Partners Healthcare Crossroads Conference

May 13, 2024

Axogen, Inc Reports First Quarter 2024 Financial Results

May 1, 2024

Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix™

April 28, 2024

Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024

April 15, 2024

Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results

March 4, 2024

Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024

February 12, 2024

Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

February 1, 2024

Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap

January 17, 2024

Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2023

January 3, 2024

Axogen Announces Promotions on Research and Development Team

January 3, 2024

Axogen Announces Plan for Leadership Transition with CEO Karen Zaderej to Retire from Company by January 2025

January 3, 2024

Axogen, Inc. Appoints Kathy Weiler to its Board of Directors

December 25, 2023

Axogen Announces Transition of Finance Team Leadership

December 5, 2023

Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 30, 2023

Axogen, Inc. to Participate at the Piper Sandler 35th Annual Healthcare Conference

November 19, 2023

Axogen, Inc. Reports 2023 Third Quarter Financial Results

November 6, 2023

Axogen, Inc. to Report Third Quarter 2023 Financial Results and Host Conference Call on November 7, 2023

October 17, 2023

Axogen, Inc. Announces Full Launch of Axoguard HA+ Nerve Protector™

September 4, 2023

Axogen to Participate at Upcoming Investor Conferences

August 30, 2023

Axogen, Inc. Begins Processing Avance® Nerve Graft at New State-of-the-Art Facility in Dayton, Ohio

August 20, 2023

Axogen, Inc. Reports 2023 Second Quarter Financial Results

August 6, 2023

Axogen to Participate at Canaccord Genuity’s 43rd Annual Growth Conference

July 26, 2023

Axogen, Inc. to report second quarter 2023 financial results and host conference call on August 7, 2023

July 25, 2023

Axogen to Participate at Jefferies Healthcare Conference

May 23, 2023

Axogen to Participate at JMP Securities Life Sciences Conference

May 11, 2023

Axogen, Inc. Reports 2023 First Quarter Financial Results

May 8, 2023

Axogen, Inc. to report first quarter 2023 financial results and host conference call on May 9, 2023

April 17, 2023

Axogen, Inc Reports 2022 Fourth Quarter and Full-Year Financial Results

March 13, 2023

Axogen, Inc. Appoints Marc Began as Executive Vice President and General Counsel

March 5, 2023

Axogen, Inc. to report fourth quarter 2022 financial results and host conference call on March 14, 2023

March 1, 2023

Axogen, Inc. Appoints Jens Schroeder Kemp as Chief Marketing Officer

February 12, 2023

Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2022

January 8, 2023

Axogen Announces Independent Publication of Comparative Nerve Gap Repair Meta-Analysis of 35 peer-reviewed studies of Allograft, Autograft, and Conduits

January 4, 2023

Axogen to Participate at J.P. Morgan 41st Annual Healthcare Conference

January 3, 2023

Axogen Patient to Ride the 2023 Donate Life Rose Parade® Float Supporting awareness of organ and tissue donation

December 18, 2022

Axogen, Inc Reports 2022 Third Quarter Financial Results

November 7, 2022

Axogen, Inc. announces the appointment of Adrian Tyndall, M.D. MPH, FACEP to its Board of Directors and the retirement of founding Director Mark Gold, M.D.

October 30, 2022

Axogen, Inc. to report third quarter 2022 financial results and host conference call on November 8, 2022

October 19, 2022

Axogen to Participate in the 77th Annual Meeting of the American Society for Surgery of the Hand

September 21, 2022

Axogen, Inc Reports 2022 Second Quarter Financial Results

August 2, 2022

Axogen, Inc. to present at Canaccord Genuity's 42nd Annual Growth Conference

July 28, 2022

Axogen, Inc. Announces Organizational Updates, Preliminary Second Quarter Revenue and Reaffirms Full-Year 2022 Financial Guidance

July 17, 2022

Axogen, Inc. Appoints William Burke to Board of Directors

July 10, 2022

Axogen, Inc. to present at the Jefferies Virtual Healthcare Conference and the JMP Securities Life Sciences Conference

May 17, 2022

Axogen, Inc Reports 2022 First Quarter Financial Results

May 3, 2022

Axogen, Inc. Announces Positive Topline Results from Phase 3 RECON(SM) Study for Avance® Nerve Graft

May 3, 2022

Axogen, Inc. to Report First Quarter 2022 Financial Results and Host Conference Call on May 4, 2022

April 12, 2022

Axogen, Inc. publishes inaugural ESG Report

March 16, 2022

Axogen, Inc. Reports 2021 Fourth Quarter and Full-Year Financial Results

February 21, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 22 calls. Every call is listed under its year.

Decks

The 5 newest of 35 decks. Every deck is listed under its year.